Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein
about
Mechanisms of Cross-protection by Influenza Virus M2-based VaccinesM2e-Based Universal Influenza A VaccinesProtection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.Production of H5N1 Influenza Virus Matrix Protein 2 Ectodomain Protein Bodies in Tobacco Plants and in Insect Cells as a Candidate Universal Influenza Vaccine.Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus.Novel vaccine strategies against emerging viruses.Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.Construction of recombinant bacmid containing m2e-ctxb and producing the fusion protein in insect cell linesAdjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.M2-based influenza vaccines: recent advances and clinical potential.Monomeric M2e antigen in VesiVax® liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e.Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant.
P2860
Q26777740-4E22CB56-3A21-48F1-9BCB-8EB57F008919Q26783493-2C82292C-DBDE-42C4-9AD7-50D5F4A8C86DQ35209148-2E95E5A3-56B0-49B6-81DE-955B610DDC7DQ35772241-6BC9BACD-E8C8-47E9-A81C-D270872B9904Q36352851-D3733D00-9846-40D1-AA16-9C3DEA4FCB9EQ36527796-02E23461-5DFC-4816-B88E-AD645D3BC98EQ36816140-D325759D-DEA1-4982-869C-A1497C6B181CQ37210056-E70ABDF4-D65A-43DC-BD4F-69A02D6E33DEQ37547653-08065505-1325-4AF2-9480-4773C1DA8B6CQ37663318-44E387FF-9376-42A8-98CB-254975443156Q38719567-B940C8FF-D2A6-48EC-9986-7FCA7C039FC8Q40571808-3D408AB3-FE86-4DF4-8E4A-B147BE22BC60Q44504298-661FED5E-9089-47F6-83B9-6E88CA1AB18AQ47159626-53BBEF06-3076-4CAA-A36C-CD05D5853A2BQ47550128-7EABB66B-A607-44FE-9E10-438B7557C3FD
P2860
Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Increased immunogenicity and p ...... sed to a tetramerizing protein
@ast
Increased immunogenicity and p ...... sed to a tetramerizing protein
@en
Increased immunogenicity and p ...... sed to a tetramerizing protein
@nl
type
label
Increased immunogenicity and p ...... sed to a tetramerizing protein
@ast
Increased immunogenicity and p ...... sed to a tetramerizing protein
@en
Increased immunogenicity and p ...... sed to a tetramerizing protein
@nl
prefLabel
Increased immunogenicity and p ...... sed to a tetramerizing protein
@ast
Increased immunogenicity and p ...... sed to a tetramerizing protein
@en
Increased immunogenicity and p ...... sed to a tetramerizing protein
@nl
P2093
P2860
P50
P1433
P1476
Increased immunogenicity and p ...... sed to a tetramerizing protein
@en
P2093
Anne-Marie Carola Andersson
Benjamin Anderschou Holbech Jensen
Kjell O Håkansson
P2860
P304
P356
10.1371/JOURNAL.PONE.0046395
P407
P577
2012-10-01T00:00:00Z